Literature DB >> 686884

Decreases in histamine forming enzyme activity of non-metastasizing fibrosarcomas in hamsters with progressive tumor growth.

T C Moore, L E Koppelman, C A Lemmi.   

Abstract

A marked and progressive decrease in the activity of the histamine forming enzyme, histidine decarboxylase (HDC), of tumors was found to be associated with the progressive growth of SV-40 virus induced and transplanted syngeneic non-metastasizing fibrosarcomas in inbred LSH Syrian hamsters. Histamine forming enzyme activity was highest in the smallest tumors (p < .005) and in the tumors with the slowest growth rate (p < .005, r - 0.84). Tumor histamine forming enzyme activity was highest for each interval of animal exposure to inoculated tumor cells in those animals which had limited their tumor growth to the smallest tumor size. These findings suggested a local anti-inflammatory effect of progressive tumor growth. Induced local inflammation by repeated intratumor injections of bradykinin markedly elevated tumor histamine forming enzyme activity above expected levels for tumors of the same size in a small group of individual animals which were sampled at random from a larger group of animals which were being studied for the tumor growth kinetics effects of repeated intralesional injections of bradykinin. Tumor histamine forming enzyme activity was highest in those animals which were managed by the frequency of injection and dose schedules which were found in the tumor growth kinetics study to be most effective in limiting tumor growth. These findings suggested that the observed anti-inflammatory effects of progressive tumor growth may be reversed by locally induced inflammation at the tumor site with beneficial effects on tumor growth.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 686884      PMCID: PMC1396736          DOI: 10.1097/00000658-197808000-00009

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  25 in total

1.  Formation and binding of histamine by rat tissues in vitro.

Authors:  R W SCHAYER
Journal:  Am J Physiol       Date:  1956-09

2.  The action of pharmacologically active substances on the flow and composition of cat hind limb lymph.

Authors:  G P Lewis; N J Winsey
Journal:  Br J Pharmacol       Date:  1970-11       Impact factor: 8.739

3.  Prolongation of rat skin allograft survival with isonicotinic acid hydrazide and methapyrilene hydrochloride.

Authors:  T C Moore; D P Thompson
Journal:  Surg Gynecol Obstet       Date:  1971-02

4.  Effective use of isoniazid and an antihistamine in clinical renal transplantation.

Authors:  T C Moore
Journal:  Surg Gynecol Obstet       Date:  1971-07

5.  Elevation in urinary and blood histamine following clinical renal transplantation.

Authors:  T C Moore; D P Thompson; R J Glassock
Journal:  Ann Surg       Date:  1971-03       Impact factor: 12.969

6.  Prostaglandins as potentiators of increased vascular permeability in inflammation.

Authors:  T J Williams; J Morley
Journal:  Nature       Date:  1973-11-23       Impact factor: 49.962

7.  Correlation of renal blood-flow indices and histamine metabolism after canine renal allografting.

Authors:  T C Moore; D P Thompson; M Hayes
Journal:  Arch Surg       Date:  1970-07

8.  Effect of semicarbazide and pyridoxine deficiency on survival of canine renal homografts.

Authors:  W A Smellie; T C Moore
Journal:  Surg Gynecol Obstet       Date:  1969-01

9.  Alterations in kinins of coronary blood from rat heart homografts.

Authors:  C A Lemmi; T S Vigran; L E Koppelmann; B M Yu; T C Moore
Journal:  Arch Surg       Date:  1975-09

10.  Prostaglandins, kinin and inflammation in the rat.

Authors:  G Thomas; G B West
Journal:  Br J Pharmacol       Date:  1974-02       Impact factor: 8.739

View more
  2 in total

1.  Substance P increases lymphocyte traffic and lymph flow through peripheral lymph nodes of sheep.

Authors:  T C Moore; J L Lami; C H Spruck
Journal:  Immunology       Date:  1989-05       Impact factor: 7.397

2.  Blood histamine and solid malignant tumors.

Authors:  C M Moriarty; J L Stucky; K W Hamburger; K D Patil; J F Foley; R R Koefoot
Journal:  J Cancer Res Clin Oncol       Date:  1988       Impact factor: 4.553

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.